Literature DB >> 28682309

Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics.

Erin T Strovel1, Tina M Cowan2, Anna I Scott2, Barry Wolf3.   

Abstract

Disclaimer: These ACMG Standards and Guidelines are intended as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these Standards and Guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of others that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, clinical laboratory geneticists should apply their professional judgment to the specific circumstances presented by the patient or specimen. Clinical laboratory scientists and geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.Biotinidase deficiency is an autosomal recessively inherited disorder of biotin recycling that is associated with neurologic and cutaneous consequences if untreated. Fortunately, the clinical features of the disorder can be ameliorated or prevented by administering pharmacological doses of the vitamin biotin. Newborn screening and confirmatory diagnosis of biotinidase deficiency encompasses both enzymatic and molecular testing approaches. These guidelines were developed to define and standardize laboratory procedures for enzymatic biotinidase testing, to delineate situations for which follow-up molecular testing is warranted, and to characterize variables that can influence test performance and interpretation of results.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28682309     DOI: 10.1038/gim.2017.84

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  86 in total

1.  Novel mutations in children with profound biotinidase deficiency from Saudi Arabia.

Authors:  R J Pomponio; P T Ozand; M Al Essa; B Wolf
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

2.  Asymptomatic adults and older siblings with biotinidase deficiency ascertained by family studies of index cases.

Authors:  T Baykal; G Gokcay; Y Gokdemir; F Demir; Y Seckin; M Demirkol; K Jensen; B Wolf
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 3.  Mutations in BTD causing biotinidase deficiency.

Authors:  J Hymes; C M Stanley; B Wolf
Journal:  Hum Mutat       Date:  2001-11       Impact factor: 4.878

4.  Comprehensive cost-utility analysis of newborn screening strategies.

Authors:  Aaron E Carroll; Stephen M Downs
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

5.  Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States.

Authors:  K J Norrgard; R J Pomponio; K L Swango; J Hymes; T R Reynolds; G A Buck; B Wolf
Journal:  Biochem Mol Med       Date:  1997-06

Review 6.  Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss.

Authors:  Barry Wolf
Journal:  Mol Genet Metab       Date:  2015-09-03       Impact factor: 4.797

7.  Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.

Authors:  Laura Vallejo-Torres; Iván Castilla; María L Couce; Celia Pérez-Cerdá; Elena Martín-Hernández; Mercé Pineda; Jaume Campistol; Arantzazu Arrospide; Stephen Morris; Pedro Serrano-Aguilar
Journal:  Pediatrics       Date:  2015-07-13       Impact factor: 7.124

8.  Phenotypic variation in biotinidase deficiency.

Authors:  B Wolf; R E Grier; R J Allen; S I Goodman; C L Kien; W D Parker; D M Howell; D L Hurst
Journal:  J Pediatr       Date:  1983-08       Impact factor: 4.406

9.  Neonatal screening for biotinidase deficiency.

Authors:  D T Forman; D D Bankson; W E Highsmith
Journal:  Ann Clin Lab Sci       Date:  1992 May-Jun       Impact factor: 1.256

Review 10.  Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have".

Authors:  Barry Wolf
Journal:  Genet Med       Date:  2012-01-05       Impact factor: 8.822

View more
  7 in total

Review 1.  Inborn Errors of Metabolism in Pediatric Epilepsy.

Authors:  Anna S Cosnahan; Christopher T Campbell
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

2.  High Incidence of Partial Biotinidase Deficiency in the First 3 Years of a Regional Newborn Screening Program in Italy.

Authors:  Daniela Semeraro; Sara Verrocchio; Giulia Di Dalmazi; Claudia Rossi; Damiana Pieragostino; Ilaria Cicalini; Rossella Ferrante; Silvia Di Michele; Liborio Stuppia; Cristiano Rizzo; Francesca Romana Lepri; Antonio Novelli; Carlo Dionisi-Vici; Vincenzo De Laurenzi; Ines Bucci
Journal:  Int J Environ Res Public Health       Date:  2022-07-02       Impact factor: 4.614

3.  Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population.

Authors:  Rai-Hseng Hsu; Yin-Hsiu Chien; Wuh-Liang Hwu; I-Fan Chang; Hui-Chen Ho; Shi-Ping Chou; Tzu-Ming Huang; Ni-Chung Lee
Journal:  Orphanet J Rare Dis       Date:  2019-01-07       Impact factor: 4.123

Review 4.  Biotinidase Deficiency: Prevalence, Impact And Management Strategies.

Authors:  Ebru Canda; Sema Kalkan Uçar; Mahmut Çoker
Journal:  Pediatric Health Med Ther       Date:  2020-05-04

5.  Partial Biotinidase Deficiency Revealed Imbalances in Acylcarnitines Profile at Tandem Mass Spectrometry Newborn Screening.

Authors:  Ilaria Cicalini; Damiana Pieragostino; Cristiano Rizzo; Sara Verrocchio; Daniela Semeraro; Mirco Zucchelli; Silvia Di Michele; Carlo Dionisi-Vici; Liborio Stuppia; Vincenzo De Laurenzi; Ines Bucci; Claudia Rossi
Journal:  Int J Environ Res Public Health       Date:  2021-02-09       Impact factor: 3.390

6.  Reconciling newborn screening and a novel splice variant in BTD associated with partial biotinidase deficiency: a BabySeq Project case report.

Authors:  Jaclyn B Murry; Kalotina Machini; Ozge Ceyhan-Birsoy; Amy Kritzer; Joel B Krier; Matthew S Lebo; Shawn Fayer; Casie A Genetti; Grace E VanNoy; Timothy W Yu; Pankaj B Agrawal; Richard B Parad; Ingrid A Holm; Amy L McGuire; Robert C Green; Alan H Beggs; Heidi L Rehm
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-08-01

7.  1H-Nuclear Magnetic Resonance Analysis of Urine as Diagnostic Tool for Organic Acidemias and Aminoacidopathies.

Authors:  Ninna Pulido; Johana M Guevara-Morales; Alexander Rodriguez-López; Álvaro Pulido; Jhon Díaz; Ru Angelie Edrada-Ebel; Olga Y Echeverri-Peña
Journal:  Metabolites       Date:  2021-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.